ClinicalTrials.gg
Active, not recruitingNCT04994717Updated Jun 30, 2026

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

A Phase 3 interventional study of Blinatumomab and Low-intensity chemotherapy regimen in Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL), sponsored by Amgen. Active, not recruiting at 192 sites in 32 countries. Open to participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
303
Allocation
Randomized
Ages
40 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
10th of 61
303 · median 67
Started
2021
with 6 others
Phase 3
11 of 61
4 open now
Primary completion
2029-09
later than 31 of 38 live
Registered
40th of 61
by date
Lead sponsor
9 of 61
Amgen

Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 10th largest by enrollment, is one of 7 that started in 2021, is one of 11 in phase 3, reaches primary completion later than 31 of the 38 other live ones, and was the 40th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 40 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy.

03

Conditions studied

  • Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Keywords

  • Newly Diagnosed Philadelphia (Ph)-negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
  • Blinatumomab
  • Low-intensity Chemotherapy
  • GMALL HyperCVAD
04

Who can participate

Ages eligible
40 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Age ≥ 55 years at the time of . OR

Age 40 to \< 55 years of age if at least 1 of the following comorbidities at the time of informed consent:

  • history of grades 3 and 4 pancreatitis
  • diabetes mellitus with end-organ damage
  • severe liver disease such as cirrhosis stage 2 with portal hypertension or history of esophageal variceal bleeding and (AST)/alanine aminotransferase (ALT) > 10 x (ULN) (liver cirrhosis must be confirmed by )
  • (BMI) ≥ 40 combined with relevant comorbidities such as metabolic syndrome
  • Any further combination of documented severe comorbidities that the investigator judges to be incompatible with administering an intensive pediatric based, adult adapted standard chemotherapy regimen but still compatible with the suggested protocol for older participants in both the experimental and the SOC arm. The participant history will be reviewed by the medical monitor during screening to determine enrollment acceptability based on a standard list with types of comorbidities allowed.

    • Participants with newly diagnosed Philadelphia (Ph)-negative B-cell precursor acute lymphoblastic leukemia (ALL)
    • (ECOG) performance status ≤ 2, higher ECOG score allowed if due to underlying leukemia
    • All participants must have adequate organ function as defined below:
  • renal: estimated based on MDRD calculation ≥ 50 mL/min/1.73 m\^2
  • liver function: total ≤ 2x upper limit of normal (ULN; unless Gilbert's Disease or if liver involvement with leukemia); exception for participants 40 to \< 55 years of age if they have a comorbidity listed above: severe liver disease such as cirrhosis stage 2 with portal hypertension or history of esophageal variceal bleeding and AST/ALT > 10 x ULN (liver cirrhosis must be confirmed by biopsy)
  • cardiac: (LVEF) ≥ 50% and no , uncontrolled, or active cardiovascular disease (eg, myocardial infarction or stroke within 3 months). Consult with medical monitor as needed.

Exclusion criteria

Exclusion Criteria:

  • Active central nervous system (CNS) leukemia (i.e., CNS 3 leukemia, confirmed by lumbar puncture) not resolved with IT chemotherapy during screening.
  • History of other within the past 3 years, with the following exceptions:

    • Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before enrollment and felt to be at low risk for recurrence by the treating physician Note: History of other malignancy (eg, multiple myeloma) treated with immunomodulatory drugs (eg, lenalidomide, thalidomide) in the past 3 years is an exclusion.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated cervical carcinoma in situ without evidence of disease
    • Adequately treated breast ductal carcinoma in situ without evidence of disease
    • Prostatic intraepithelial neoplasia without evidence of prostate cancer
    • Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ
  • CNS pathology or event such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychiatric conditions that preclude the use of high dose of
  • Current disease or history of autoimmune disease with potential CNS involvement
  • Known infection with (HIV)
  • Known infection with chronic or active infection with (eg, hepatitis b surface [HBs] antigen reactive or quantifiable hepatitis b virus [HBV] viral load) or virus (HCV) (eg, HCV RNA [qualitative] is detected).

Active hepatitis B and C based on the following results:

  • positive for hepatitis B surface antigen (HepBsAg) (indicative of chronic hepatitis B or recent acute hepatitis B)
  • negative HepBsAg and positive for hepatitis B core antibody: negative HBV DNA by PCR result is necessary to enroll.
  • positive Hepatitis C virus antibody (HepCAb): negative hepatitis C virus RNA by PCR result is necessary to enroll.

    • Participant with symptoms and/or clinical signs and/or radiographic and/or sonographic signs that indicate an acute or uncontrolled chronic infection.
    • Cancer chemotherapy for this newly diagnosed B cell ALL before the start of protocol-required therapy with the exception of IT chemotherapy or optional pre-phase (debulking) chemotherapy. Radiation to a spot lesion such as chloroma or lytic lesion of bone or vertebrae for pain or vertebral stabilization is allowed.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
303 participants (actual)

Study arms

  • Experimental
    Safety Run-in: Blinatumomab alternating with low-intensity chemotherapy

    The safety run-in will be performed prior to initiating the phase 3 randomized part of the study. This safety run-in is to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The safety run-in also evaluates a shorter dose step interval from (4 days instead of 7 days) and a 1-week (instead of 2-week) drug free interval between blinatumomab cycles. Blinatumomab will be infused at a lower dose for 4 days and increase to a higher dose on Day 5 of the infusion for the remainder of the infusion.

    Drug: Blinatumomab · Drug: Low-intensity chemotherapy regimen

  • Experimental
    Phase 3: Blinatumomab alternating with low-intensity chemotherapy

    Participants will receive blinatumomab alternating with low-intensity chemotherapy.

    Drug: Blinatumomab · Drug: Low-intensity chemotherapy regimen

  • Active comparator
    Phase 3: Standard of care (SOC) chemotherapy

    Participants will receive 1 of 2 SOC chemotherapy regimens (GMALL or HyperCVAD) per investigator's choice.

    Drug: SOC chemotherapy regimen

Interventions

  • Continuous intravenous (cIV) infusion

    Also known as: Blincyto®

  • DrugLow-intensity chemotherapy regimen

    Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.

  • DrugSOC chemotherapy regimen

    Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.

06

What researchers measure

Primary outcomes

  1. Safety run-in: Number of Participants who Experience Treatment-emergent Adverse Events (TEAEs)

    Number and percentage of participants who experience one or more TEAE, serious TEAE, treatment-related adverse events, and adverse events of interest.

    Time frame: Up to approximately 5 years

  2. Phase 3: Event-free Survival (EFS)

    Time from randomization (enrollment) until treatment failure, relapse or death from any cause, whichever is earlier. Treatment failure is defined as not achieving a hematological complete CR with MRD response \<10-4 by the end of the initial disease assessment period. Relapse is defined as hematologic relapse, extramedullary relapse, and/or molecular relapse (MRD positivity \>= 10\^-3), whichever occurs earlier, in participants with prior achievement of hematologic CR with MRD response \<10\^-4. Participants without an event will be censored at their last evaluable disease assessment date.

    Time frame: Up to approximately 5 years

  3. Phase 3: Overall Survival (OS)

    OS is defined as time from randomization (enrollment) until death due to any cause.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Safety run-in: Complete Remission (CR) Rate by the End of Initial Disease Assessment Period

    Time frame: Baseline to Week 14

  2. Safety run-in: Minimal Residual Disease (MRD) Response by the End of Initial Disease Assessment Period

    MRD response is defined as the percentage of participants who achieve a response of \< 10\^-4 measured by polymerase chain reaction (PCR).

    Time frame: Baseline to Week 14

  3. Safety run-in: Relapse-free Survival (RFS)

    RFS: In participants who achieve CR, the time from first achievement of this response until date of the first relapse including hematologic relapse, extramedullary relapse, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 5 years

  4. Safety run-in: Minimal Residual Disease (MRD) Relapse Free Survival (RFS)

    MRD RFS: In participants who achieve CR with MRD response, the time from first achievement of this response until date of of the first relapse including molecular relapse, hematological relapse, and/or extramedullary relapse, or death due to any cause, whichever occurs first. (Molecular relapse will be defined 2 ways: MRD\>= 10\^-3 and MRD\>=10\^-4. Participants without an event will be censored at their last evaluable disease assessment date.

    Time frame: Up to approximately 5 years

  5. Safety run-in: Steady State Concentration (Css) of Blinatumomab

    Time frame: Up to approximately 34 weeks

  6. Safety run-in: Clearance (CL) of Blinatumomab

    Time frame: Up to approximately 34 weeks

  7. Phase 3: Change from Baseline to End of Initial Disease Assessment Period in Fatigue Score

    Fatigue score will be measured by Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue - Short Form 7a.

    Time frame: Baseline to Week 14

  8. Phase 3: Change from Baseline to End of Initial Disease Assessment Period in Pain Score

    Pain score will be measured by Brief Pain Inventory - Short Form (BPI-SF); Item 3: pain at its worst in the last 24 hours.

    Time frame: Baseline to Week 14

  9. Phase 3: Change from Baseline to End of Initial Disease Assessment Period in Global Health Status

    Global health status will be measured by the Quality of Life Questionnaire (QLQ)-C30 global health status quality of life scale.

    Time frame: Baseline to Week 14

  10. Phase 3: Change from Baseline to End of Initial Disease Assessment Period in Physical Function

    Physical function will be measured by the QLQ-C30 functional scale.

    Time frame: Baseline to Week 14

  11. Phase 3: Change from Baseline to End of Initial Disease Assessment Period in Nausea and Vomiting

    Nausea and vomiting will be measured by the QLQ-C30 symptom scale.

    Time frame: Baseline to Week 14

  12. Phase 3: Complete Remission (CR) Rate by the End of Initial Disease Assessment Period

    Time frame: Baseline to Week 14

  13. Phase 3: Minimal Residual Disease (MRD) Response by the End of Initial Disease Assessment Period

    MRD response is defined as the percentage of participants who achieve a response of \< 10\^4 measured by polymerase chain reaction (PCR).

    Time frame: Baseline to Week 14

  14. Phase 3: Relapse-free Survival (RFS)

    RFS: In participants who achieve CR, the time from first achievement of this response until the date of the first relapse including hematologic relapse, extra medullary relapse, or death due to any cause, whichever occurs first. Participants without an event will be censored at their last evaluable disease assessment date.

    Time frame: Up to approximately 5 years

  15. Phase 3: Minimal Residual Disease (MRD) Relapse Free Survival (RFS)

    In participants who achieve CR with MRD response, the time from first achievement of this response until date of the first relapse including molecular relapse, hematologic relapse, and/or extramedullary relapse, or death due to any cause, whichever occurs first. Molecular relapse will be defined 2 ways: MRD\>= 10\^-3 and MRD\>= 10\^-4. Participants without an event will be censored at their last evaluable disease assessment date

    Time frame: Up to approximately 5 years

  16. Phase 3: Minimal Residual Disease (MRD) Over Time

    Time frame: Up to approximately 5 years

  17. Phase 3: Number of Participants who Experience Treatment-emergent Adverse Events (TEAEs)

    Number and percentage of participants who experience one or more TEAE, serious TEAE, treatment-related adverse events, and adverse events of interest.

    Time frame: Up to approximately 5 years

  18. Phase 3: Number of Participants who Experience Cluster of Differentiation (CD) 19 Positive and Negative Relapse by Flow Cytometry for Bone Marrow

    Time frame: Up to approximately 5 years

  19. Phase 3: Number of Participants who Experience Cluster of Differentiation (CD) 19 Positive and Negative Relapse Identified by Immunohistochemistry or Flow Cytometry for Cerebrospinal Fluid

    Time frame: Up to end of safety follow up (approximately 44 months)

  20. Phase 3: Number of Participants who Experience Cluster of Differentiation (CD) 19 Positive and Negative Relapse for Extramedullary Sites other than Cerebrospinal Fluid

    Time frame: Up to end of safety follow up (approximately 44 months)

  21. Phase 3: Rate of Lineage Switch to Acute Myeloid Leukemia (AML)

    Time frame: Up to end of safety follow up (approximately 44 months)

  22. Phase 3: Localization of Relapse by Clinical Assessment

    Time frame: Up to end of safety follow up (approximately 44 months)

  23. Phase 3: Mortality Rate in Participants who Experience Complete Remission (CR)

    Time frame: Up to approximately 5 years

  24. Phase 3: Number of Participants who have Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Participants who Experience Continuous First Complete Remission (CR)

    Time frame: Up to approximately 5 years

  25. Phase 3: Mortality Rate in Participants who Experience Complete Remission (CR) after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)

    Time frame: Up to approximately 5 years

  26. Phase 3: Relapse Rate Following Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)

    Time frame: Up to approximately 5 years

  27. Phase 3: Time to Deterioration using the Fatigue Score

    Fatigue score will be measured by PROMIS Fatigue-Short Form 7a.

    Time frame: Up to approximately 5 years

  28. Phase 3: Time to Improvements using the Fatigue Score

    Fatigue score will be measured by PROMIS Fatigue-Short Form 7a.

    Time frame: Up to approximately 5 years

  29. Phase 3: Time to Deterioration using the Pain Score

    Pain score will be measured by BPI-SF; Item 3: pain at its worst in the last 24 hours.

    Time frame: Up to approximately 5 years

  30. Phase 3: Time to Improvements using the Pain Score

    Pain score will be measured by BPI-SF; Item 3: pain at its worst in the last 24 hours.

    Time frame: Up to approximately 5 years

  31. Phase 3: Change from Baseline in Global Health Status, Physical Function, Nausea/Vomiting, and All Other Subscales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 will include global health status, physical functioning, emotional functioning, cognitive functioning, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, diarrhea, and financial difficulties will be measured by EORTC QLQ-C30.

    Time frame: Baseline to end of study (up to approximately 5 years)

  32. Phase 3: Time to Deterioration for Global Health Status, Physical Function, Nausea/Vomiting, and All Other Subscales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, diarrhea, and financial difficulties will be measured by EORTC QCQ-C30.

    Time frame: Up to approximately 5 years

  33. Phase 3: Time to Improvements for Global Health Status, Physical Function, Nausea/Vomiting, and All Other Subscales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    Global health status, physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, diarrhea, and financial difficulties will be measured by EORTC QCQ-C30.

    Time frame: Up to approximately 5 years

  34. Steady State Concentration of Blinatumomab

    Time frame: Up to approximately Day 36

  35. Clearance of Blinatumomab

    Time frame: Up to approximately Day 36

07

Study locations

192 sites

Showing the first 100 of 192 sites across 32 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Sep 2029, 94 months after the start.

Of 59 phase 3 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 86 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 104. This study's planned 94 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2021
First posted
Aug 6, 2021
StartActual
Nov 2, 2021
Primary completionEst.
Sep 7, 2029
CompletionEst.
Jun 30, 2031
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04994717
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 6, 2021
Start date
Nov 2, 2021
Primary completion
Sep 7, 2029 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Jun 30, 2026

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion